Clinical Trial Update: Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

View source ↗

Summary

An observational study evaluating acalabrutinib in patients with chronic lymphocytic leukemia in the United Kingdom is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia, CLL | Status: RECRUITING